Emerging nanomedicines of paclitaxel for cancer treatment

Malignant tumor is still a leading threat to human health. Despite the rapid development of targeted therapeutic strategies, any treatment specifically acting on single target would inevitably suffer from tumor resistance, largely due to the genetic instability and variability of tumor cells. Thus, traditional therapies such as broadspectrum chemotherapy would certainly occupy an important position in clinical cancer therapy. Nevertheless, most chemotherapeutic drugs have long been criticized for unsatisfactory therapeutic efficacy with severe off-target toxicity. Although several chemotherapeutic nanomedicines with improved therapeutic safety have been applied in clinics, the therapeutic outcomes still do not fulfill expectation. To address this challenge, enormous efforts have been devoted to developing novel nano-formulations for efficient delivery of chemotherapeutic drugs. Herein, we aim to outline the latest progression in the emerging nanomedicines of paclitaxel (PTX), with special attention to the functional nanocarriers, self-delivering prodrug-nanoassemblies and combination nanotherapeutics of PTX. Finally, the challenges and opportunities of these functional PTX nano medicines in clinical translation are spotlighted.

Automated summary

Malignant tumor remains a major threat to human health. Although targeted therapeutic strategies have developed rapidly, treatments that act on a single target are prone to tumor resistance. Therefore, traditional broadspectrum chemotherapy still plays a critical role in clinical cancer therapy. However, most chemotherapeutic drugs have unsatisfactory therapeutic efficacy and severe off-target toxicity. To overcome this, researchers have focused on developing novel nano-formulations for efficient delivery of chemotherapeutic drugs.